clinical trial · NCT07422285
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Amgen·phase1·recruiting·n = 400
Healthy ParticipantsPharmacokineticsEvolocumab Drug Substance AEvolocumab Drug Substance B
brief summary
The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
started
Jan 16, 2026
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Apr 16, 2026
official title
An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol